MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Bio-Techne Corp

Fermé

SecteurSoins de santé

52.64

Résumé

Variation du prix de l'action

24h

Actuel

Min

51.72

Max

53.56

Chiffres clés

By Trading Economics

Revenu

-12M

23M

Ventes

19M

316M

P/E

Moyenne du Secteur

62.09

39.564

Rendement du dividende

0.62

Marge bénéficiaire

7.144

Employés

3,100

EBITDA

-36M

39M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+24.11% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.62%

2.40%

Prochains Résultats

6 août 2025

Date du Prochain Dividende

29 août 2025

Date du Prochain Détachement de Dividende

18 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-2.5B

8.1B

Ouverture précédente

52.64

Clôture précédente

52.64

Sentiment de l'Actualité

By Acuity

63%

37%

56 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Bio-Techne Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 juil. 2025, 15:46 UTC

Principaux Mouvements du Marché

BitMine Shares Fall After Closing of $250 Million Private Placement

9 juil. 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 juil. 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 juil. 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 juil. 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 juil. 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9 juil. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juil. 2025, 20:26 UTC

Résultats

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 juil. 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 juil. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 juil. 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9 juil. 2025, 17:07 UTC

Market Talk
Acquisitions, Fusions, Rachats

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 juil. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9 juil. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juil. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juil. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 juil. 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 juil. 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 juil. 2025, 16:14 UTC

Acquisitions, Fusions, Rachats

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 juil. 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 juil. 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 juil. 2025, 15:31 UTC

Principaux Mouvements du Marché

BitMine Shares Fall After Closing of $250M Private Placement

9 juil. 2025, 15:31 UTC

Market Talk
Acquisitions, Fusions, Rachats

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 juil. 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 juil. 2025, 14:36 UTC

Acquisitions, Fusions, Rachats

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 juil. 2025, 14:31 UTC

Acquisitions, Fusions, Rachats

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 juil. 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9 juil. 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Comparaison

Variation de prix

Bio-Techne Corp prévision

Objectif de Prix

By TipRanks

24.11% hausse

Prévisions sur 12 Mois

Moyen 65.38 USD  24.11%

Haut 80 USD

Bas 51 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

7

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

49.67 / 50.24Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Strong Bearish Evidence

Sentiment

By Acuity

56 / 376Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.